Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 137

1.

Adrenergic-mediated increases in INHBA drive CAF phenotype and collagens.

Nagaraja AS, Dood RL, Armaiz-Pena G, Kang Y, Wu SY, Allen JK, Jennings NB, Mangala LS, Pradeep S, Lyons Y, Haemmerle M, Gharpure KM, Sadaoui NC, Rodriguez-Aguayo C, Ivan C, Wang Y, Baggerly K, Ram P, Lopez-Berestein G, Liu J, Mok SC, Cohen L, Lutgendorf SK, Cole SW, Sood AK.

JCI Insight. 2018 Jun 7;3(11). pii: 122389. doi: 10.1172/jci.insight.122389. [Epub ahead of print] No abstract available.

2.

Immune cell profiling in cancer: molecular approaches to cell-specific identification.

Lyons YA, Wu SY, Overwijk WW, Baggerly KA, Sood AK.

NPJ Precis Oncol. 2017 Aug 15;1(1):26. doi: 10.1038/s41698-017-0031-0. eCollection 2017. Review.

3.

ADH1B promotes mesothelial clearance and ovarian cancer infiltration.

Gharpure KM, Lara OD, Wen Y, Pradeep S, LaFargue C, Ivan C, Rupaimoole R, Hu W, Mangala LS, Wu SY, Nagaraja AS, Baggerly K, Sood AK.

Oncotarget. 2018 May 18;9(38):25115-25126. doi: 10.18632/oncotarget.25344. eCollection 2018 May 18.

4.

Defining Survivorship Trajectories Across Patients With Solid Tumors: An Evidence-Based Approach.

Dood RL, Zhao Y, Armbruster SD, Coleman RL, Tworoger S, Sood AK, Baggerly KA.

JAMA Oncol. 2018 Jun 2. doi: 10.1001/jamaoncol.2018.2761. [Epub ahead of print]

PMID:
29860375
5.

Experimental Design, Randomization, and Validation.

Baggerly K.

Clin Chem. 2018 May 18. pii: clinchem.2017.273334. doi: 10.1373/clinchem.2017.273334. [Epub ahead of print] No abstract available.

PMID:
29776951
6.

A Survey on Data Reproducibility and the Effect of Publication Process on the Ethical Reporting of Laboratory Research.

Boulbes DR, Costello T, Baggerly K, Fan F, Wang R, Bhattacharya R, Ye X, Ellis LM.

Clin Cancer Res. 2018 Jul 15;24(14):3447-3455. doi: 10.1158/1078-0432.CCR-18-0227. Epub 2018 Apr 11.

PMID:
29643062
7.

A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers.

Berger AC, Korkut A, Kanchi RS, Hegde AM, Lenoir W, Liu W, Liu Y, Fan H, Shen H, Ravikumar V, Rao A, Schultz A, Li X, Sumazin P, Williams C, Mestdagh P, Gunaratne PH, Yau C, Bowlby R, Robertson AG, Tiezzi DG, Wang C, Cherniack AD, Godwin AK, Kuderer NM, Rader JS, Zuna RE, Sood AK, Lazar AJ, Ojesina AI, Adebamowo C, Adebamowo SN, Baggerly KA, Chen TW, Chiu HS, Lefever S, Liu L, MacKenzie K, Orsulic S, Roszik J, Shelley CS, Song Q, Vellano CP, Wentzensen N; Cancer Genome Atlas Research Network, Weinstein JN, Mills GB, Levine DA, Akbani R.

Cancer Cell. 2018 Apr 9;33(4):690-705.e9. doi: 10.1016/j.ccell.2018.03.014. Epub 2018 Apr 2.

8.

Detection of Bladder Cancer in Urine Sediments by a Novel Multicolor Fluorescence In Situ Hybridization (Quartet) Test.

Zhang S, Wang Y, Bondaruk J, Majewski T, Yao H, Lee S, Lee JG, Cogdell D, Lotan Y, Dinney C, Wei P, Baggerly K, Czerniak B.

Eur Urol Focus. 2018 Feb 7. pii: S2405-4569(18)30018-X. doi: 10.1016/j.euf.2018.01.017. [Epub ahead of print]

PMID:
29428551
9.

Macrophage depletion through colony stimulating factor 1 receptor pathway blockade overcomes adaptive resistance to anti-VEGF therapy.

Lyons YA, Pradeep S, Wu SY, Haemmerle M, Hansen JM, Wagner MJ, Villar-Prados A, Nagaraja AS, Dood RL, Previs RA, Hu W, Zhao Y, Mak DH, Xiao Z, Melendez BD, Lizee GA, Mercado-Uribe I, Baggerly KA, Hwu P, Liu J, Overwijk WW, Coleman RL, Sood AK.

Oncotarget. 2017 Aug 24;8(57):96496-96505. doi: 10.18632/oncotarget.20410. eCollection 2017 Nov 14.

10.

Prevalence of Aflatoxin-Associated TP53R249S Mutation in Hepatocellular Carcinoma in Hispanics in South Texas.

Jiao J, Niu W, Wang Y, Baggerly K, Ye Y, Wu X, Davenport D, Almeda JL, Betancourt-Garcia MM, Forse RA, Stevenson HL, Watt GP, McCormick JB, Fisher-Hoch SP, Beretta L.

Cancer Prev Res (Phila). 2018 Feb;11(2):103-112. doi: 10.1158/1940-6207.CAPR-17-0235-AT. Epub 2017 Oct 31.

PMID:
29089331
11.

Genetic Polymorphisms of CFH and ARMS2 Do Not Predict Response to Antioxidants and Zinc in Patients with Age-Related Macular Degeneration: Independent Statistical Evaluations of Data from the Age-Related Eye Disease Study.

Assel MJ, Li F, Wang Y, Allen AS, Baggerly KA, Vickers AJ.

Ophthalmology. 2018 Mar;125(3):391-397. doi: 10.1016/j.ophtha.2017.09.008. Epub 2017 Oct 9.

PMID:
29032853
12.

Surface PD-L1, E-cadherin, CD24, and VEGFR2 as markers of epithelial cancer stem cells associated with rapid tumorigenesis.

Jinesh GG, Manyam GC, Mmeje CO, Baggerly KA, Kamat AM.

Sci Rep. 2017 Aug 29;7(1):9602. doi: 10.1038/s41598-017-08796-z.

13.

Carcinoma of the urethra.

Zhang M, Adeniran AJ, Vikram R, Tamboli P, Pettaway C, Bondaruk J, Liu J, Baggerly K, Czerniak B.

Hum Pathol. 2018 Feb;72:35-44. doi: 10.1016/j.humpath.2017.08.006. Epub 2017 Aug 18.

PMID:
28827100
14.

Adrenergic-mediated increases in INHBA drive CAF phenotype and collagens.

Nagaraja AS, Dood RL, Armaiz-Pena G, Kang Y, Wu SY, Allen JK, Jennings NB, Mangala LS, Pradeep S, Lyons Y, Haemmerle M, Gharpure KM, Sadaoui NC, Rodriguez-Aguayo C, Ivan C, Wang Y, Baggerly K, Ram P, Lopez-Berestein G, Liu J, Mok SC, Cohen L, Lutgendorf SK, Cole SW, Sood AK.

JCI Insight. 2017 Aug 17;2(16). pii: 93076. doi: 10.1172/jci.insight.93076. [Epub ahead of print]

15.

Maternal 25(OH)D concentrations ≥40 ng/mL associated with 60% lower preterm birth risk among general obstetrical patients at an urban medical center.

McDonnell SL, Baggerly KA, Baggerly CA, Aliano JL, French CB, Baggerly LL, Ebeling MD, Rittenberg CS, Goodier CG, Mateus Niño JF, Wineland RJ, Newman RB, Hollis BW, Wagner CL.

PLoS One. 2017 Jul 24;12(7):e0180483. doi: 10.1371/journal.pone.0180483. eCollection 2017.

16.

Sarcomatoid Renal Cell Carcinoma Has a Distinct Molecular Pathogenesis, Driver Mutation Profile, and Transcriptional Landscape.

Wang Z, Kim TB, Peng B, Karam J, Creighton C, Joon A, Kawakami F, Trevisan P, Jonasch E, Chow CW, Canales JR, Tamboli P, Tannir N, Wood C, Monzon F, Baggerly K, Varella-Garcia M, Czerniak B, Wistuba I, Mills G, Shaw K, Chen K, Sircar K.

Clin Cancer Res. 2017 Nov 1;23(21):6686-6696. doi: 10.1158/1078-0432.CCR-17-1057. Epub 2017 Jul 14.

PMID:
28710314
17.

High-throughput profiling of signaling networks identifies mechanism-based combination therapy to eliminate microenvironmental resistance in acute myeloid leukemia.

Zeng Z, Liu W, Tsao T, Qiu Y, Zhao Y, Samudio I, Sarbassov DD, Kornblau SM, Baggerly KA, Kantarjian HM, Konopleva M, Andreeff M.

Haematologica. 2017 Sep;102(9):1537-1548. doi: 10.3324/haematol.2016.162230. Epub 2017 Jun 28.

18.

Elevation of TP53 Autoantibody Before CA125 in Preclinical Invasive Epithelial Ovarian Cancer.

Yang WL, Gentry-Maharaj A, Simmons A, Ryan A, Fourkala EO, Lu Z, Baggerly KA, Zhao Y, Lu KH, Bowtell D, Jacobs I, Skates SJ, He WW, Menon U, Bast RC Jr; AOCS Study Group.

Clin Cancer Res. 2017 Oct 1;23(19):5912-5922. doi: 10.1158/1078-0432.CCR-17-0284. Epub 2017 Jun 21.

PMID:
28637689
19.

Quality of life among long-term survivors of advanced stage ovarian cancer: A cross-sectional approach.

Lutgendorf SK, Shinn E, Carter J, Leighton S, Baggerly K, Guindani M, Fellman B, Matzo M, Slavich GM, Goodman MT, Tew W, Lester J, Moore KM, Karlan BY, Levine DA, Sood AK.

Gynecol Oncol. 2017 Jul;146(1):101-108. doi: 10.1016/j.ygyno.2017.05.008. Epub 2017 May 17.

20.

Effect of Vitamin D and Calcium Supplementation on Cancer Incidence in Older Women: A Randomized Clinical Trial.

Lappe J, Watson P, Travers-Gustafson D, Recker R, Garland C, Gorham E, Baggerly K, McDonnell SL.

JAMA. 2017 Mar 28;317(12):1234-1243. doi: 10.1001/jama.2017.2115.

PMID:
28350929
21.

Integrated MicroRNA-mRNA Profiling Identifies Oncostatin M as a Marker of Mesenchymal-Like ER-Negative/HER2-Negative Breast Cancer.

Bottai G, Diao L, Baggerly KA, Paladini L, Győrffy B, Raschioni C, Pusztai L, Calin GA, Santarpia L.

Int J Mol Sci. 2017 Jan 19;18(1). pii: E194. doi: 10.3390/ijms18010194.

22.

Aurora Kinase A is a Biomarker for Bladder Cancer Detection and Contributes to its Aggressive Behavior.

Mobley A, Zhang S, Bondaruk J, Wang Y, Majewski T, Caraway NP, Huang L, Shoshan E, Velazquez-Torres G, Nitti G, Lee S, Lee JG, Fuentes-Mattei E, Willis D, Zhang L, Guo CC, Yao H, Baggerly K, Lotan Y, Lerner SP, Dinney C, McConkey D, Bar-Eli M, Czerniak B.

Sci Rep. 2017 Jan 19;7:40714. doi: 10.1038/srep40714.

23.

Functional CAR models for large spatially correlated functional datasets.

Zhang L, Baladandayuthapani V, Zhu H, Baggerly KA, Majewski T, Czerniak BA, Morris JS.

J Am Stat Assoc. 2016;111(514):772-786. doi: 10.1080/01621459.2015.1042581. Epub 2016 Aug 18.

24.

Co-localized genomic regulation of miRNA and mRNA via DNA methylation affects survival in multiple tumor types.

Doecke JD, Wang Y, Baggerly K.

Cancer Genet. 2016 Oct;209(10):463-473. doi: 10.1016/j.cancergen.2016.09.001. Epub 2016 Sep 12.

PMID:
27810075
25.

Meta-Analysis of the Luminal and Basal Subtypes of Bladder Cancer and the Identification of Signature Immunohistochemical Markers for Clinical Use.

Dadhania V, Zhang M, Zhang L, Bondaruk J, Majewski T, Siefker-Radtke A, Guo CC, Dinney C, Cogdell DE, Zhang S, Lee S, Lee JG, Weinstein JN, Baggerly K, McConkey D, Czerniak B.

EBioMedicine. 2016 Oct;12:105-117. doi: 10.1016/j.ebiom.2016.08.036. Epub 2016 Aug 25.

26.

Biphasic components of sarcomatoid clear cell renal cell carcinomas are molecularly similar to each other, but distinct from, non-sarcomatoid renal carcinomas.

Sircar K, Yoo SY, Majewski T, Wani K, Patel LR, Voicu H, Torres-Garcia W, Verhaak RG, Tannir N, Karam JA, Jonasch E, Wood CG, Tamboli P, Baggerly KA, Aldape KD, Czerniak B.

J Pathol Clin Res. 2015 Jul 7;1(4):212-24. doi: 10.1002/cjp2.23. eCollection 2015 Oct.

27.

A miR-192-EGR1-HOXB9 regulatory network controls the angiogenic switch in cancer.

Wu SY, Rupaimoole R, Shen F, Pradeep S, Pecot CV, Ivan C, Nagaraja AS, Gharpure KM, Pham E, Hatakeyama H, McGuire MH, Haemmerle M, Vidal-Anaya V, Olsen C, Rodriguez-Aguayo C, Filant J, Ehsanipour EA, Herbrich SM, Maiti SN, Huang L, Kim JH, Zhang X, Han HD, Armaiz-Pena GN, Seviour EG, Tucker S, Zhang M, Yang D, Cooper LJ, Ali-Fehmi R, Bar-Eli M, Lee JS, Ram PT, Baggerly KA, Lopez-Berestein G, Hung MC, Sood AK.

Nat Commun. 2016 Apr 4;7:11169. doi: 10.1038/ncomms11169.

28.

Gene Expression Profile of the Clinically Aggressive Micropapillary Variant of Bladder Cancer.

Guo CC, Dadhania V, Zhang L, Majewski T, Bondaruk J, Sykulski M, Wronowska W, Gambin A, Wang Y, Zhang S, Fuentes-Mattei E, Kamat AM, Dinney C, Siefker-Radtke A, Choi W, Baggerly KA, McConkey D, Weinstein JN, Czerniak B.

Eur Urol. 2016 Oct;70(4):611-620. doi: 10.1016/j.eururo.2016.02.056. Epub 2016 Mar 15.

29.

Role of Increased n-acetylaspartate Levels in Cancer.

Zand B, Previs RA, Zacharias NM, Rupaimoole R, Mitamura T, Nagaraja AS, Guindani M, Dalton HJ, Yang L, Baddour J, Achreja A, Hu W, Pecot CV, Ivan C, Wu SY, McCullough CR, Gharpure KM, Shoshan E, Pradeep S, Mangala LS, Rodriguez-Aguayo C, Wang Y, Nick AM, Davies MA, Armaiz-Pena G, Liu J, Lutgendorf SK, Baggerly KA, Eli MB, Lopez-Berestein G, Nagrath D, Bhattacharya PK, Sood AK.

J Natl Cancer Inst. 2016 Jan 26;108(6):djv426. doi: 10.1093/jnci/djv426.

30.

NDN is an imprinted tumor suppressor gene that is downregulated in ovarian cancers through genetic and epigenetic mechanisms.

Yang H, Das P, Yu Y, Mao W, Wang Y, Baggerly K, Wang Y, Marquez RT, Bedi A, Liu J, Fishman D, Lu Z, Bast RC Jr.

Oncotarget. 2016 Jan 19;7(3):3018-32. doi: 10.18632/oncotarget.6576.

31.

A genome-scale screen reveals context-dependent ovarian cancer sensitivity to miRNA overexpression.

Shields BB, Pecot CV, Gao H, McMillan E, Potts M, Nagel C, Purinton S, Wang Y, Ivan C, Kim HS, Borkowski RJ, Khan S, Rodriguez-Aguayo C, Lopez-Berestein G, Lea J, Gazdar A, Baggerly KA, Sood AK, White MA.

Mol Syst Biol. 2015 Dec 11;11(12):842. doi: 10.15252/msb.20156308.

32.

Post-hoc analysis of vitamin D status and reduced risk of preterm birth in two vitamin D pregnancy cohorts compared with South Carolina March of Dimes 2009-2011 rates.

Wagner CL, Baggerly C, McDonnell S, Baggerly KA, French CB, Baggerly L, Hamilton SA, Hollis BW.

J Steroid Biochem Mol Biol. 2016 Jan;155(Pt B):245-51. doi: 10.1016/j.jsbmb.2015.10.022. Epub 2015 Nov 10.

33.

Combined Tumor Suppressor Defects Characterize Clinically Defined Aggressive Variant Prostate Cancers.

Aparicio AM, Shen L, Tapia EL, Lu JF, Chen HC, Zhang J, Wu G, Wang X, Troncoso P, Corn P, Thompson TC, Broom B, Baggerly K, Maity SN, Logothetis CJ.

Clin Cancer Res. 2016 Mar 15;22(6):1520-30. doi: 10.1158/1078-0432.CCR-15-1259. Epub 2015 Nov 6.

34.

Intratumoral morphologic and molecular heterogeneity of rhabdoid renal cell carcinoma: challenges for personalized therapy.

Singh RR, Murugan P, Patel LR, Voicu H, Yoo SY, Majewski T, Mehrotra M, Wani K, Tannir N, Karam JA, Jonasch E, Wood CG, Creighton CJ, Medeiros LJ, Broaddus RR, Tamboli P, Baggerly KA, Aldape KD, Czerniak B, Luthra R, Sircar K.

Mod Pathol. 2015 Sep;28(9):1225-35. doi: 10.1038/modpathol.2015.68. Epub 2015 Jun 26.

35.

The ZNF304-integrin axis protects against anoikis in cancer.

Aslan B, Monroig P, Hsu MC, Pena GA, Rodriguez-Aguayo C, Gonzalez-Villasana V, Rupaimoole R, Nagaraja AS, Mangala S, Han HD, Yuca E, Wu SY, Ivan C, Moss TJ, Ram PT, Wang H, Gol-Chambers A, Ozkayar O, Kanlikilicer P, Fuentes-Mattei E, Kahraman N, Pradeep S, Ozpolat B, Tucker S, Hung MC, Baggerly K, Bartholomeusz G, Calin G, Sood AK, Lopez-Berestein G.

Nat Commun. 2015 Jun 17;6:7351. doi: 10.1038/ncomms8351.

36.

Clinical next generation sequencing to identify actionable aberrations in a phase I program.

Boland GM, Piha-Paul SA, Subbiah V, Routbort M, Herbrich SM, Baggerly K, Patel KP, Brusco L, Horombe C, Naing A, Fu S, Hong DS, Janku F, Johnson A, Broaddus R, Luthra R, Shaw K, Mendelsohn J, Mills GB, Meric-Bernstam F.

Oncotarget. 2015 Aug 21;6(24):20099-110.

37.

Regulating the stability and localization of CDK inhibitor p27(Kip1) via CSN6-COP1 axis.

Choi HH, Guma S, Fang L, Phan L, Ivan C, Baggerly K, Sood A, Lee MH.

Cell Cycle. 2015;14(14):2265-73. doi: 10.1080/15384101.2015.1046655. Epub 2015 May 6.

38.

A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia.

Daver N, Boumber Y, Kantarjian H, Ravandi F, Cortes J, Rytting ME, Kawedia JD, Basnett J, Culotta KS, Zeng Z, Lu H, Richie MA, Garris R, Xiao L, Liu W, Baggerly KA, Jabbour E, O'Brien S, Burger J, Bendall LJ, Thomas D, Konopleva M.

Clin Cancer Res. 2015 Jun 15;21(12):2704-14. doi: 10.1158/1078-0432.CCR-14-2888. Epub 2015 Feb 27.

39.

Optimized Prediction of Extreme Treatment Outcomes in Ovarian Cancer.

Misganaw B, Ahsen E, Singh N, Baggerly KA, Unruh A, White MA, Vidyasagar M.

Cancer Inform. 2016 Mar 21;14(Suppl 5):45-55. doi: 10.4137/CIN.S30803. eCollection 2015.

40.

Expression of sulfotransferase SULT1A1 in cancer cells predicts susceptibility to the novel anticancer agent NSC-743380.

Huang X, Cao M, Wang L, Wu S, Liu X, Li H, Zhang H, Wang RY, Sun X, Wei C, Baggerly KA, Roth JA, Wang M, Swisher SG, Fang B.

Oncotarget. 2015 Jan 1;6(1):345-54.

41.

Clinically relevant microRNAs in ovarian cancer.

Zhang S, Lu Z, Unruh AK, Ivan C, Baggerly KA, Calin GA, Li Z, Bast RC Jr, Le XF.

Mol Cancer Res. 2015 Mar;13(3):393-401. doi: 10.1158/1541-7786.MCR-14-0424. Epub 2014 Oct 10. Review.

42.

Reverse-phase protein array for prediction of patients at low risk of developing bone metastasis from breast cancer.

Hayashi N, Manyam GC, Gonzalez-Angulo AM, Niikura N, Yamauchi H, Nakamura S, Hortobágyi GN, Baggerly KA, Ueno NT.

Oncologist. 2014 Sep;19(9):909-14. doi: 10.1634/theoncologist.2014-0099. Epub 2014 Aug 12.

43.

BRCA2 inhibition enhances cisplatin-mediated alterations in tumor cell proliferation, metabolism, and metastasis.

Rytelewski M, Tong JG, Buensuceso A, Leong HS, Maleki Vareki S, Figueredo R, Di Cresce C, Wu SY, Herbrich SM, Baggerly KA, Romanow L, Shepherd T, Deroo BJ, Sood AK, Chambers AF, Vincent M, Ferguson PJ, Koropatnick J.

Mol Oncol. 2014 Dec;8(8):1429-40. doi: 10.1016/j.molonc.2014.05.017. Epub 2014 Jun 6.

44.

Molecular biomarkers of residual disease after surgical debulking of high-grade serous ovarian cancer.

Tucker SL, Gharpure K, Herbrich SM, Unruh AK, Nick AM, Crane EK, Coleman RL, Guenthoer J, Dalton HJ, Wu SY, Rupaimoole R, Lopez-Berestein G, Ozpolat B, Ivan C, Hu W, Baggerly KA, Sood AK.

Clin Cancer Res. 2014 Jun 15;20(12):3280-8. doi: 10.1158/1078-0432.CCR-14-0445. Epub 2014 Apr 22.

45.

Focal adhesion kinase: an alternative focus for anti-angiogenesis therapy in ovarian cancer.

Stone RL, Baggerly KA, Armaiz-Pena GN, Kang Y, Sanguino AM, Thanapprapasr D, Dalton HJ, Bottsford-Miller J, Zand B, Akbani R, Diao L, Nick AM, DeGeest K, Lopez-Berestein G, Coleman RL, Lutgendorf S, Sood AK.

Cancer Biol Ther. 2014 Jul;15(7):919-29. doi: 10.4161/cbt.28882. Epub 2014 Apr 23.

46.

Notch3 pathway alterations in ovarian cancer.

Hu W, Liu T, Ivan C, Sun Y, Huang J, Mangala LS, Miyake T, Dalton HJ, Pradeep S, Rupaimoole R, Previs RA, Han HD, Bottsford-Miller J, Zand B, Kang Y, Pecot CV, Nick AM, Wu SY, Lee JS, Sehgal V, Ram P, Liu J, Tucker SL, Lopez-Berestein G, Baggerly KA, Coleman RL, Sood AK.

Cancer Res. 2014 Jun 15;74(12):3282-93. doi: 10.1158/0008-5472.CAN-13-2066. Epub 2014 Apr 17.

47.

2'-OMe-phosphorodithioate-modified siRNAs show increased loading into the RISC complex and enhanced anti-tumour activity.

Wu SY, Yang X, Gharpure KM, Hatakeyama H, Egli M, McGuire MH, Nagaraja AS, Miyake TM, Rupaimoole R, Pecot CV, Taylor M, Pradeep S, Sierant M, Rodriguez-Aguayo C, Choi HJ, Previs RA, Armaiz-Pena GN, Huang L, Martinez C, Hassell T, Ivan C, Sehgal V, Singhania R, Han HD, Su C, Kim JH, Dalton HJ, Kovvali C, Keyomarsi K, McMillan NA, Overwijk WW, Liu J, Lee JS, Baggerly KA, Lopez-Berestein G, Ram PT, Nawrot B, Sood AK.

Nat Commun. 2014 Mar 12;5:3459. doi: 10.1038/ncomms4459.

48.

Autocrine effects of tumor-derived complement.

Cho MS, Vasquez HG, Rupaimoole R, Pradeep S, Wu S, Zand B, Han HD, Rodriguez-Aguayo C, Bottsford-Miller J, Huang J, Miyake T, Choi HJ, Dalton HJ, Ivan C, Baggerly K, Lopez-Berestein G, Sood AK, Afshar-Kharghan V.

Cell Rep. 2014 Mar 27;6(6):1085-1095. doi: 10.1016/j.celrep.2014.02.014. Epub 2014 Mar 6.

49.

Preclinical and early clinical evaluation of the oral AKT inhibitor, MK-2206, for the treatment of acute myelogenous leukemia.

Konopleva MY, Walter RB, Faderl SH, Jabbour EJ, Zeng Z, Borthakur G, Huang X, Kadia TM, Ruvolo PP, Feliu JB, Lu H, Debose L, Burger JA, Andreeff M, Liu W, Baggerly KA, Kornblau SM, Doyle LA, Estey EH, Kantarjian HM.

Clin Cancer Res. 2014 Apr 15;20(8):2226-35. doi: 10.1158/1078-0432.CCR-13-1978. Epub 2014 Feb 28.

50.

Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy.

Choi W, Porten S, Kim S, Willis D, Plimack ER, Hoffman-Censits J, Roth B, Cheng T, Tran M, Lee IL, Melquist J, Bondaruk J, Majewski T, Zhang S, Pretzsch S, Baggerly K, Siefker-Radtke A, Czerniak B, Dinney CP, McConkey DJ.

Cancer Cell. 2014 Feb 10;25(2):152-65. doi: 10.1016/j.ccr.2014.01.009.

Supplemental Content

Loading ...
Support Center